###### Article summary

Strengths and limitations of this study
=======================================

-   Randomised, double-blind, placebo-controlled crossover design.

-   Use of an established and robust model to simultaneously assess endothelial vasomotor tone as well as endogenous fibrinolysis: two important and complementary measures of vascular function.

-   Limitations: modest sample size.

Introduction {#s1}
============

Dietary fish or fish oil supplements containing ω-3 fatty acids may protect against cardiovascular disease.[@R1] Clinical trials have demonstrated beneficial effects on mortality or cardiac events in patients with coronary heart disease.[@R2; @R3; @R4] However, the mechanisms through which they confer cardiac benefits are uncertain. Although an effect on ventricular arrhythmias has been thought to be important due to an observed reduction in sudden death,[@R5] [@R6] subsequent studies have failed to clearly demonstrate an antiarrhythmic effect.[@R7] An alternative mechanism may, therefore, be an effect on the vascular endothelium, as acute myocardial infarction due to plaque rupture and subsequent coronary thrombosis remains the most common cause of sudden cardiac death.[@R8]

The endothelium regulates vascular tone and blood flow, and mediates thrombosis through the production of factors that influence fibrinolysis and platelet activation. The endogenous fibrinolytic system is responsible for the dissolution of arterial thrombi and is regulated by the endothelium-derived profibrinolytic factor, tissue plasminogen activator (t-PA) and its inhibitor, plasminogen-activator inhibitor type 1 (PAI-1).[@R9] The rapid release of t-PA from the endothelium is vital, with thrombus dissolution being more effective if t-PA is incorporated early during thrombus formation.[@R10]

Endothelial cells regulate thrombosis through the release of paracrine factors that mediate platelet function. Activated platelets can bind to leucocytes through a P-selectin-dependent mechanism,[@R11] and these interactions can also be modulated by the CD40 receptor and its ligand.[@R12] Formation of platelet--leucocyte aggregates or ligation of CD40 can mediate an array of proinflammatory and prothrombotic effects, thereby contributing to endothelial injury and atherothrombosis.[@R13]

Patients with coronary heart disease demonstrate impaired endothelial function,[@R14] in addition to increased platelet--monocyte aggregation and upregulation of the CD40/CD40 ligand system.[@R15] [@R16] We have recently demonstrated that ω-3 fatty acid supplements improve endogenous fibrinolysis and endothelial function in healthy cigarette smokers, a group at high risk of adverse cardiac events.[@R17] Previously, we have shown that dietary fish intake reduces platelet--monocyte aggregation in man.[@R18] We, therefore, hypothesised that ω-3 fatty acid supplementation would improve endothelial vasomotor function, endogenous fibrinolysis, and markers of platelet and monocyte activation in patients with coronary heart disease.

Methods {#s2}
=======

Study participants {#s2a}
------------------

Twenty patients with a myocardial infarction at least 3 months previously were recruited to participate in the study. Myocardial infarction was defined as any two of the following: typical clinical history, ECG changes (Q waves in 2 contiguous leads) or elevation of cardiac markers (CKmB or troponin). All participants gave written informed consent.. Exclusion criteria included dietary fish allergy or intolerance, consumption of more than one fish meal per week, renal or hepatic failure, or any intercurrent illness likely to be associated with an inflammatory response. The first patient was randomised in December 2004 and the last study visit took place in June 2006. There were logistical delays in the analysis of frozen plasma samples and the final data became available for analysis in June 2009.

Study design {#s2b}
------------

This was a prospective, double-blind, placebo-controlled, randomised crossover trial. Participants were randomised to receive either ω-3 fatty acid supplements (2 g/day, Omacor capsules, Pronova, Norway) or matching placebo capsules (2 g/day olive oil capsules; Eurocaps Ltd, Gwent, Australia) for a 6-week period. After a 4-week washout phase, participants crossed over to the opposite treatment arm for a further 6-week period. The ω-3 Fatty acid supplements and placebo were packaged and dispensed in identical containers by the Royal Infirmary of Edinburgh Pharmacy. All study participants and investigators were blinded to the study allocation. The randomisation schedule was generated by an investigator not involved in the study, and securely kept in the Royal Infirmary of Edinburgh Pharmacy. The ω-3 fatty acid capsules contained 85--88% eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethyl esters in a ratio of 1.2:1. The ω-3 fatty acid capsules as well as olive oil placebo contained 4 mg α-tocopherol. All 20 participants had peripheral blood taken for fasting lipid profile, plasma fatty acid analysis and flow cytometric analysis of platelet activation at baseline and at the end of each treatment period. Two patients withdrew from the study: one was withdrawn after being admitted with unstable angina and a second was lost to follow-up. A subset of 12 participants also underwent measurement of forearm blood flow (FBF) and endogenous fibrinolysis at the end of each treatment period.

Blood collection protocol {#s2c}
-------------------------

Peripheral venous blood was drawn from a large antecubital vein with a 19-gauge needle and anticoagulated with EDTA (1.6 mg/mL, Sarstedt Monovette) and the direct thrombin inhibitor d-phenylalanine-l-prolyl-l-arginine chloromethyl ketone (75 μM, PPACK, Cambridge Biosciences). Whole blood anticoagulated with PPACK was immunolabelled within 5 min of phlebotomy for subsequent flow cytometric analysis. Plasma was prepared from blood anticoagulated with sodium EDTA by centrifugation (1500×*g* for 30 min). Plasma samples were stored at −70°C until analysis.

Flow cytometry {#s2d}
--------------

The following reagents were used: fluorscein isothiocyanate (FITC)-conjugated CD42a (GRP-P, IgG1), FITC-conjugated CD14 (UCHM1, IgG2a), phycoerythrin (PE)-conjugated CD40 (LOB7/6, IgG1), and their appropriate isotype controls (Serotec Ltd, Oxford, UK) as well as PE-conjugated CD154 (TRAP1, IgG1), PE-conjugated CD14 (Tuk-4, IgG2a), PE-conjugated CD 62P (IE3, IgG2a) and their appropriate isotype controls (Dako Cytomation, Buckinghamshire, UK) and FACS-Lyse (Becton-Dickinson; Cowley, UK). Aliquots of whole blood (60 μL) anticoagulated with PPACK were incubated with appropriate antibodies and their isotype matched controls for 20 min at room temperature. To evaluate platelet--monocyte aggregates and CD40 on monocytes, samples were fixed and red cells lysed by the addition of 500 μL of FACS-Lyse solution. To evaluate platelet surface P-selectin and CD40 ligand, samples were fixed with 1% paraformaldehyde. Samples were analysed using a Coulter EPICS XL flow cytometer equipped with a 488 nm wavelength laser (Beckman Coulter, High Wycombe, UK) within 6 h of labelling. Monocytes and platelets were identified by gating for CD14 and CD42a positive cells, respectively. Platelet--monocyte aggregates were defined as monocytes positive for CD42a. Analyses were performed using EXPO 32 software (Beckman Coulter).

Plasma fatty acid analysis {#s2e}
--------------------------

The fatty acid composition of plasma phospholipids was determined from blood anticoagulated with EDTA. Total lipids were recovered from 500 μL of plasma using dichloromethane--methanol (2:1) containing 0.005% butyrated hydroxytoluene as an antioxidant (Folch extraction). Phospholipids were isolated by solid phase extraction using aminopropyl silica columns (IST International), and fatty acids converted into methyl esters by transmethylation with 0.5 M sodium methoxide. Fatty acid methyl ester analysis was performed with an HP-INNOWAX capillary column (Agilent Technologies). Peaks were identified by comparison of retention times with known fatty acid methyl ester standards and quantified using an internal standard. Plasma total phospholipid fatty acids were expressed as the individual fractions of fatty acids and fatty acid groups as relative values (% of total fatty acids). The mean coefficient of variation for the assay was 2.4%.

Vascular studies {#s2f}
----------------

Studies were conducted in a quiet temperature controlled room (22--25°C). Participants fasted for 6 h prior to the study and avoided caffeine and alcohol for the preceding 24 h. Blood pressure and heart rate were recorded throughout the study using a semi-automated non-invasive oscillometric sphygmomanometer (OMRON 705 IT, Kyoto, Japan).

All participants underwent brachial artery cannulation with a 27-standard wire gauge steel needle under controlled conditions. After a 30-min baseline saline infusion, acetylcholine at 5, 10 and 20 µg/min (endothelium-dependent vasodilator that does not release t-PA; Merck Biosciences), substance P at 2, 4 and 8 pmol/min (endothelium-dependent vasodilator that releases t-PA; Clinalfa, Switzerland) and sodium nitroprusside at 2, 4 and 8 µg/min (endothelium-independent vasodilator that does not release t-PA; David Bull Laboratories) were infused for 6 min at each dose. The three vasodilators were separated by 20-min saline infusions and given in a randomised order.

FBF was measured in infused and non-infused arms by venous occlusion plethysmography with mercury-in-silicone elastomer strain gauges as described previously.[@R19] Venous cannulas (17-gauge) were inserted into large subcutaneous veins of the antecubital fossae of both arms. Blood (10 mL) was withdrawn simultaneously from each arm at baseline and during infusion of each dose of substance P and collected into acidified buffered citrate (Stabilyte tubes, Biopool International; for t-PA assays) and into citrate (BD Vacutainer; for PAI-1 assays). Samples were kept on ice before being centrifuged at 2000*g* for 30 min at 4°C. Platelet-free plasma was decanted and stored at −80°C before assay. Plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit; Technoclone, Vienna, Austria) and PAI-1 antigen and activity (Elitest PAI-1 Antigen and Zymutest PAI-1 Activity; Hyphen Biomed, Neuville-Sur-Oise, France) concentrations were determined by ELISAs. Haematocrit was determined by capillary tube centrifugation at baseline.

Data analysis and statistical methods {#s2g}
-------------------------------------

Continuous variables are reported as mean±SE of the mean. The pre-specified primary endpoint was endothelial vasomotor and fibrinolytic function. The sample size of n=12 was based on power calculations derived from previous studies giving 90% power to detect a 17% difference in the mean t-PA release at a significance level of 5%.[@R19] The pre-specified secondary endpoint was platelet and monocyte activation. The sample size of n=20 was based on power calculations derived from previous studies, giving 90% power to detect a 5% difference in mean platelet--monocyte aggregation at a significance level of 5%. Forearm plethysmographic data were analysed as described previously.[@R17] Estimated net release of plasma t-PA has been defined previously as the product of the infused forearm plasma flow (based on the mean haematocrit and the infused FBF) and the concentration difference between the infused and non-infused arms.[@R19] Statistical analyses were performed using one-way and two-way ANOVA with Bonferroni\'s post-tests for multiple comparisons where appropriate. The statistical methods for each analysis are detailed in the relevant figure and table legends. All calculations were performed using GraphPad Prism (Graph Pad Software).

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

Participant flow through the study including a CONSORT diagram is included in the online supplementary file. Patients were relatively young and well treated in terms of blood pressure control and lipid profile ([table 1](#BMJOPEN2013003054TB1){ref-type="table"}). The mean and median times from myocardial infarction were 12 and 16 months, respectively. Patients were on standard medical therapy including aspirin, β-blockers, statins and ACE-inhibitors, and over half had undergone revascularisation post-MI.

###### 

Baseline characteristics.

  ------------------------------------------------------- ---------
  Age, years                                              53±3
  Body mass index, kg/m^2^                                28±1
  Systolic blood pressure, mm Hg                          137±5
  Diastolic blood pressure, mm Hg                         78±3
  Heart rate, bpm                                         60±2
  Total cholesterol, mmol/L                               4.2±0.2
  LDL cholesterol, mmol/L                                 2.3±0.2
  HDL cholesterol, mmol/L                                 1.1±0.1
  Chol:HDL chol ratio                                     3.8±0.2
  Triacylglycerol, mmol/L                                 1.6±0.2
  Fasting glucose, mmol/L                                 5.4±0.1
  Time from MI, months                                    16±4
  Revascularisation post-MI, %                            56
  Current or ex-smoker, %                                 61
  Hypertension, %                                         11
  Diabetes mellitus, %                                    0
  Hyperlipidemia, %                                       78
  Family history of premature coronary heart disease, %   33
  Medical therapy                                         
   Aspirin, %                                             100
   Clopidogrel, %                                         11
   ACE-inhibitor/ angiotensin-receptor blocker, %         56
   β-Blocker, %                                           78
   Statin, %                                              100
  ------------------------------------------------------- ---------

HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; Mean±SEM.

Effect of ω-3 fatty acid supplementation on plasma phospholipid fatty acid composition {#s3b}
--------------------------------------------------------------------------------------

Dietary supplementation with ω-3 fatty acids led to a marked increase in EPA as a percentage of plasma phospholipids compared with both baseline (3.7±0.4% vs 2.0±0.2%, p\<0.0001) and placebo (3.7±0.4% vs 1.7±0.1%, p\<0.0001; [table 2](#BMJOPEN2013003054TB2){ref-type="table"}). There was also an increase in DHA compared with baseline (5.6±0.2% vs 4.8±0.3%, p\<0.01) and placebo (5.6±0.2% vs 4.4±0.3%, p\<0.0001; [table 2](#BMJOPEN2013003054TB2){ref-type="table"}). We did not detect any carryover of EPA or DHA after 6 weeks of placebo in the group who had ω-3 fatty acids first (data not shown). There was a reduction in the plasma phospholipid percentage of arachidonic acid, but no effect on α-linolenic acid, linoleic acid, palmitic acid, stearic acid or oleic acid with either ω-3 fatty acid supplements or olive oil placebo ([table 2](#BMJOPEN2013003054TB2){ref-type="table"}).

###### 

Effect of ω-3 fatty acid supplementation on plasma phospholipid fatty acid composition.

                     Baseline   ω-3        Placebo    p Value
  ------------------ ---------- ---------- ---------- -----------
  EPA                2.0±0.2    3.7±0.4    1.7±0.1    p\<0.0001
  DHA                4.8±0.3    5.6±0.2    4.4±0.3    p\<0.0001
  α-Linolenic acid   0.3±0.01   0.3±0.02   0.3±0.03   0.3
  Arachidonic acid   12.5±0.4   11.0±0.3   11.6±0.5   0.0005
  Linoleic acid      18.8±0.6   19.0±0.6   20.0±0.6   0.1
  Palmitic acid      28.2±0.4   27.9±0.3   28.2±0.3   0.6
  Stearic acid       13.8±0.3   14.1±0.2   13.9±0.2   0.4
  Oleic acid         13.3±0.5   13.0±0.4   13.8±0.5   0.1

Mean±SEM. Data analysed using one-way ANOVA. p Values in the table are for the difference between the three means. p Values for individual comparisons are below.

EPA: baseline versus ω-3, p\<0.0001; baseline versus placebo, p=NS; ω-3 versus placebo, p\<0.0001.

DHA: baseline versus ω-3, p\<0.01; baseline versus placebo, p=NS; ω-3 versus placebo, p\<0.0001.

Arachidonic acid: baseline versus ω-3, p\<0.001; baseline versus placebo, p=0.05; ω-3 versus placebo, p=NS.

EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid.

Effect of ω-3 fatty acid supplementation on lipid profile {#s3c}
---------------------------------------------------------

Supplementation for 6 weeks with ω-3 fatty acids did not affect total cholesterol, low-density liproprotein cholesterol, high-density liproprotein cholesterol or triglycerides (data not shown).

Effect of ω-3 fatty acid supplementation on vasomotor function {#s3d}
--------------------------------------------------------------

ω-3 Fatty acid supplementation did not have any effect on systolic blood pressure, diastolic blood pressure or heart rate compared with placebo (data not shown). During forearm vascular studies substance P, acetylcholine and sodium nitroprusside led to a dose-dependent increase in absolute FBF (p\<0.0001 for all). Compared with placebo, ω-3 fatty acid supplementation did not affect endothelium-dependent vasodilation in response to acetylcholine or substance P (p=0.5 and 0.9; [figure 1](#BMJOPEN2013003054F1){ref-type="fig"}), or endothelium-independent vasodilation with sodium nitroprusside (p=0.9; [figure 1](#BMJOPEN2013003054F1){ref-type="fig"}).

![Effect of ω-3 fatty acid supplementation on absolute forearm blood flow in response to endothelium-dependent and endothelium-independent vasodilators. Statistical analyses two-way analysis of variance and Bonferroni\'s post-tests for multiple comparisons.](bmjopen2013003054f01){#BMJOPEN2013003054F1}

Effect of ω-3 fatty acid supplementation on stimulated t-PA activity {#s3e}
--------------------------------------------------------------------

Substance P infusion caused a dose-dependent increase in plasma t-PA activity concentrations after both ω-3 fatty acid supplementation and placebo (p\<0.0001; [table 3](#BMJOPEN2013003054TB3){ref-type="table"}). ω-3 Fatty acid supplementation did not affect plasma TPA activity, TPA antigen or PAI-1 concentrations compared to placebo ([table 3](#BMJOPEN2013003054TB3){ref-type="table"}). There was no difference in net release of t-PA activity after ω-3 fatty acid supplementation compared to placebo (p=0.94; [figure 2](#BMJOPEN2013003054F2){ref-type="fig"}).

###### 

Effect of ω-3 fatty acid supplementation on plasma t-PA activity concentrations.

  Substance P, pmol/min                                      ω-3 Fatty acids   Placebo                                                                       
  ---------------------------------------------------------- ----------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  t-PA activity, IU mL^−1^                                                                                                                                   
   Non-infused arm                                           0.39±0.08         0.45±0.09    0.54±0.12    0.64±0.14    0.45±0.07    0.52±0.08    0.60±0.09    0.65±0.11
   Infused arm                                               0.38±0.08         0.83±0.16    1.12±0.23    1.67±0.38    0.43±0.07    0.78±0.10    1.09±0.11    1.26±0.15
  t-PA antigen, ng mL^−1^                                                                                                                                    
   Non-infused arm                                           11.78±1.29        12.01±1.0    12.69±1.08   12.83±1.49   13.45±1.40   12.93±1.70   13.08±1.80   12.37±1.27
   Infused arm                                               11.90±1.45        13.98±1.33   13.63±1.12   14.86±1.40   12.55±1.10   12.85±1.44   13.45±1.35   13.97±1.55
  PAI-1 activity, ng mL^−1^                                                                                                                                  
   Non-infused arm                                           1.77±0.53         1.84±0.43    1.80±0.42    1.64±0.45    1.44±0.29    1.38±0.26    1.39±0.47    1.34±0.44
   Infused arm                                               2.33±0.86         2.18±0.61    2.21±0.69    1.92±0.63    1.69±0.46    1.64±0.41    1.54±0.39    1.49±0.39
  PAI-1 antigen, ng mL^−1^                                                                                                                                   
   Non-infused arm                                           39.51±9.22        40.84±7.08   39.99±6.62   38.48±5.79   45.06±7.09   43.33±6.45   44.41±6.67   44.26±7.03
   Infused arm                                               37.64±8.36        38.83±6.25   41.71±5.74   40.26±7.32   48.89±8.25   42.65±6.59   43.12±6.60   40.61±6.46
  Net t-PA antigen release, ng 100 mL^−1^ of tissue mm^−1^   0.23±0.51         −0.28±4.7    3.92±1.8     8.41±2.94    −0.87±1.1    −0.84±2.82   0.94±4.22    8.10±3.67

Mean±SEM. Data analysed using two-way analysis of variance.

Tissue plasminogen activator (t-PA) activity: dose response p\<0.0001. ω-3 Fatty acids versus placebo; p=0.83 (infused arm).

t-PA antigen: dose response p=0.7. ω-3 Fatty acids versus placebo; p=0.60 (infused arm).

Plasminogen-activator inhibitor type 1 (PAI-1) activity: dose response p=0.94. ω-3 Fatty acids versus placebo; p=0.17 (infused arm).

PAI-1 antigen: dose response p=0.67. ω-3 Fatty acids versus placebo; p=0.40 (infused arm).

Net t-PA antigen: dose response p=0.02. ω-3 Fatty acids versus placebo; p=0.62 (infused arm).

![Net release of plasma tissue plasminogen activator activity with ω-3 fatty acid supplementation and placebo. Statistical analyses two-way analysis of variance and Bonferroni\'s post-tests for multiple comparisons.](bmjopen2013003054f02){#BMJOPEN2013003054F2}

Effect of ω-3 fatty acid supplementation on platelet--monocyte aggregation and CD40/CD40 ligand {#s3f}
-----------------------------------------------------------------------------------------------

Supplementation with ω-3 fatty acids did not have any effect on platelet--monocyte aggregation, platelet--neutrophil aggregation, platelet surface expression of P-selectin or CD40L, or monocyte expression of CD40 (data not shown).

Discussion {#s4}
==========

The current study has demonstrated that dietary supplementation with ω-3 fatty acids does not affect endothelial vasomotor function or endothelial t-PA release in patients with coronary heart disease. There is also no effect on markers of platelet or monocyte activation. These findings suggest that any cardiac benefits conferred by ω-3 fatty acids in coronary heart disease are unlikely to be mediated through effects on endothelial function, endogenous fibrinolysis or platelet activation.

We do not believe the lack of effect on outcome measures in the current study is likely to have been due to poor compliance. The assessment of plasma phospholipid fatty acid composition confirmed substantial increases in the percentage of both EPA and DHA during supplementation with ω-3 fatty acids. The dose and duration of therapy with ω-3 fatty acids are also likely to have been appropriate. We used 2 g/day of ω-3 fatty acids which is similar to the amount shown to reduce mortality in secondary prevention trials.[@R2] [@R3] Although we cannot exclude an effect with a longer duration of therapy, 6 weeks of supplementation caused a large increase in the plasma phospholipid content of ω-3 fatty acids and has previously been long enough to demonstrate clear effects on vascular function and platelet activation.[@R20; @R21; @R22]

ω-3 Fatty acids have previously been shown to have inconsistent effects on endothelial function. Although some studies have reported beneficial effects in a variety of populations including healthy volunteers,[@R22] patients with hyperlipidaemia,[@R21] [@R23] diabetes mellitus[@R24] and heart failure,[@R25] others have not found any improvement.[@R26; @R27; @R28] Our findings are in contrast to previous studies in coronary heart disease which demonstrated an improvement in endothelial function with ω-3 fatty acids.[@R20] [@R29] [@R30] These discrepancies could be partly due to differences in study populations or concomitant medication. However, previous studies were all either not randomised or double-blinded, and lacked a control group or placebo. Indeed, our trial is the first double-blinded, placebo-controlled trial investigating the effect of ω-3 fatty acids on endothelial vasomotor function in coronary heart disease; we therefore believe that our study design and findings are likely to be robust.

We also found that ω-3 fatty acids did not augment endogenous fibrinolysis in coronary heart disease. Previous results have varied widely and it has been concluded that ω-3 fatty acids are unlikely to influence the fibrinolytic system.[@R31] While some studies have reported a beneficial impact on fibrinolytic parameters,[@R32] [@R33] others have found an adverse effect[@R34] or no effect.[@R26] [@R35; @R36; @R37] However, previous studies have only measured basal plasma t-PA concentrations that do not reflect the local capacity for acute endothelial t-PA release.[@R9] [@R38] It is the rapid endogenous release of t-PA from the endothelium which regulates the dissolution of thrombus and is of greater pathophysiological relevance. We used an established model of acute endothelial t-PA release that predicts cardiovascular outcome,[@R19] [@R39] but found no effect of ω-3 fatty acid supplementation on acute endogenous fibrinolytic capacity in coronary heart disease.

There are several possible explanations for the lack of effect of ω-3 fatty acids on endothelial function and endogenous fibrinolysis observed in the present coronary heart disease population. The patients were all well treated with modern cardio-active medication known to influence endothelial vasomotor function.[@R40] [@R41] In contrast, patients in previous studies demonstrating improved endothelial function[@R20] [@R29] and cardiac outcomes[@R2] [@R3] with ω-3 fatty acids were much less likely to be taking HMG CoA reductase inhibitors or ACE inhibitors. It is conceivable that endothelial function cannot be further improved by the addition of ω-3 fatty acids in coronary heart disease patients already treated with modern medical therapy. This possibility is supported by the most recent large clinical trials which found a low rate of cardiac events in patients on optimal medical therapy post-myocardial infarction, which could not be improved with ω-3 fatty acid supplementation.[@R42; @R43; @R44]

However, concomitant medication may not fully explain the neutral effects on endogenous fibrinolysis. While lipid-lowering therapy improves endothelial vasomotor function, it has not been found to influence acute t-PA release.[@R45] ACE inhibitors only augment bradykinin induced t-PA release; they do not affect t-PA release stimulated by substance P.[@R46] Therefore, there may be other factors that explain why ω-3 fatty acid supplementation can improve endogenous fibrinolytic capacity in healthy cigarette smokers but not in patients with coronary heart disease. Perhaps, the most likely explanation is that the coronary heart disease group was considerably older and may have a dysfunctional endothelium and fibrinolytic system less responsive to dietary interventional measures.

Circulating platelet--monocyte aggregates are increased in stable coronary heart disease and acute coronary syndromes, consistent with an important role in both the development of atherosclerotic lesions and in acute thrombosis.[@R15] We have previously demonstrated that moderate intake of oil-rich fish can significantly reduce platelet--monocyte aggregation.[@R18] However, we did not observe any effect of ω-3 fatty acid supplements on these measures of platelet and monocyte activation in the current study. It is possible that our previous results were due to another active ingredient in oily fish rather than ω-3 fatty acids, and we cannot exclude a dose--effect of ω-3 fatty acids on platelet activation. ω-3 Fatty acids also had no effect on monocyte expression of CD40 or platelet surface CD40 ligand, consistent with previous studies which found no effect of either ω-3 fatty acids or dietary fish on soluble CD40 ligand.[@R18] [@R47]

Our study has potential limitations that should be acknowledged. First, the sample size is relatively small which raises the possibility of a type II error due to lack of power. However, the sample size was based on separate power calculations for the vascular function and the platelet monocyte studies, and we have previously detected modest changes in these outcome measures with similar sample sizes.[@R17] [@R18] Although it is possible, we lacked power to detect very small changes; we believe the study had sufficient power to detect any clinically relevant effects of ω-3 fatty acids. Second, as we did not measure fatty acids at the beginning of the second treatment stage we cannot fully exclude the possibility of some carryover of EPA or DHA into the early placebo phase in the group receiving ω-3 fatty acids first. However, we feel any such effect would be modest and unlikely to alter the study outcomes.

Conclusions {#s5}
===========

We have demonstrated that ω-3 fatty acid supplementation does not affect endothelial function, endogenous fibrinolytic capacity or markers of platelet and monocyte activation in patients with stable coronary heart disease. A major strength of our study is the use of a robust model to simultaneously assess endothelial vasomotor tone as well as endogenous fibrinolysis: two important and complementary measures of vascular function. Our results suggest that any potential cardiac benefits conferred by ω-3 fatty acids in this patient group are unlikely to be mediated by effects on endothelial function or the fibrinolytic system.
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